Biofrontera acquires US Ameluz/RhodoLED rights, cuts royalty to 12%, gets $11M financing

Biofrontera Inc.

Acquires all US assets for Ameluz and RhodoLED including NDA and patents from Biofrontera AG.
Effective royalty rate reduced from 25-35% of net sales to 12% (15% above $65M revenue).
Receives $11M investment led by Rosalind Advisors and AIGH Capital Management, funding to profitability.
Biofrontera AG to receive 10% post-money equity stake in Biofrontera Inc., aligning long-term interests.
First tranche of $8.5M funded at signing; second tranche of $2.5M due upon final asset transfer agreement by Sep 30, 2025.

item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.